Barclays’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-9,304
| Closed | -$512K | – | 5371 |
|
|
2022
Q2 | $512K | Sell |
9,304
-13,196
| -59% | -$692K | ﹤0.01% | 2824 |
|
|
2022
Q1 | $721K | Buy |
+22,500
| New | +$646K | ﹤0.01% | 2646 |
|
|
2019
Q4 | – | Sell |
-3
| Closed | – | – | 7019 |
|
|
2019
Q3 | $0 | Sell |
3
-5
| -63% | -$96 | ﹤0.01% | 7310 |
|
|
2019
Q2 | $0 | Buy |
+8
| New | +$387 | ﹤0.01% | 7440 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 7461 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7523 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7520 |
|
|
2018
Q2 | – | Sell |
-143
| Closed | -$14.3K | – | 7429 |
|
|
2018
Q1 | $12K | Buy |
143
+99
| +225% | +$11.2K | ﹤0.01% | 6612 |
|
|
2017
Q4 | $7K | Buy |
+44
| New | +$4.23K | ﹤0.01% | 6611 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7132 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 7056 |
|
|
2017
Q1 | – | Sell |
-135
| Closed | -$7.85K | – | 7080 |
|
|
2016
Q4 | $8K | Buy |
135
+103
| +322% | +$6.42K | ﹤0.01% | 5995 |
|
|
2016
Q3 | $2K | Sell |
32
-163
| -84% | -$12.6K | ﹤0.01% | 6298 |
|
|
2016
Q2 | $16K | Buy |
195
+190
| +3,800% | +$36.2K | ﹤0.01% | 5376 |
|
|
2016
Q1 | $1K | Sell |
5
-8
| -62% | -$2.56K | ﹤0.01% | 6039 |
|
|
2015
Q4 | $8K | Buy |
+13
| New | +$8.79K | ﹤0.01% | 5470 |
|
Other funds holding SRRA
Barclays's SRRA Position: Q3 2022 in Review
Barclays sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 9,304 shares — an estimated $512K sold.
Barclays first reported a position in SRRA in Q4 2015 and held it in 11 quarters. The position peaked at $721K in Q1 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.
- Barclays reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Barclays sold 9,304 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $512K.
- Barclays first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2015 and held it in 11 quarters.
- Barclays's Sierra Oncology, Inc. Common Stock position peaked at $721K in Q1 2022.
- 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.
Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.